Men's Health

A genomic test capable of predicting the probability of developing metastatic prostate cancer outperformed existing clinical risk factors for predicting biochemical failure and distant metastasis following radiation therapy, researchers reported at the Genitourinary Cancers Symposium in San Francisco.

Separate studies at the Genitourinary Cancers Symposium highlighted the utility of prostate cancer tests Prolaris and ConfirmMDx for Prostate Cancer for treatment planning and identifying aggressive disease, respectively.

The androgen-receptor blocker enzalutamide (XTANDI) increases survival by 29% in men with metastatic castration-resistant prostate cancer (mCRPC) and delays progression of the disease by 81%, according to new phase III study results in men who had not previously received chemotherapy.

Drugs and devices in the pipeline from Medivation, Astellas Pharma, Teva Pharmaceuticals, Boston Scientific, Northwest Biotherapeutics, and Generex Biotechnology.

New products and services from UroGPO, Caldera Medical, Auxilium Pharmaceuticals, VIVUS, and Jeffrey Albaugh, PhD, APRN.

Erectile dysfunction has been added the U.S. Surgeon General’s list of diseases caused by smoking.

Higher levels of melatonin, a hormone involved in the sleep-wake cycle, may suggest decreased risk for developing advanced prostate cancer, according to a recent study.

In men with nonobstructive azoospermia, frozen and fresh testicular sperm offer similar fertilization and pregnancy rates, according to the authors of a meta-analysis who say it is the first such study to specifically address the fresh-versus-frozen debate in this population.

Urologists across the country offer their opinions on high-intensity focused ultrasound.

Men who walked at a fast pace prior to prostate cancer diagnosis had more regularly shaped blood vessels in their prostate tumors compared with men who walked slowly, providing a potential explanation for why exercise is linked to improved outcomes for men with prostate cancer.

Type of surgical approach-open or robot assisted-appears to have no effect on specific clinical outcomes in patients undergoing radical prostatectomy for high-risk prostate cancer, nor does the procedure influence the pathway subsequent therapy might follow, according to a recent study.

More than 85% of patients undergoing robot-assisted laparoscopic prostatectomy may not require opioid analgesia either immediately post-op, in hospital, or upon release, according to a recent study.

A recently published study found that a small percentage of men who seek infertility treatment are potentially hurting their ability to have children by taking testosterone supplements.

A lawsuit was filed against both the urologist and the radiologist involved in the treatment of the kidney stone, claiming that he was not informed of the abnormality on the left kidney noted on the CT scan and the recommendation for follow-up.

Although testosterone use has increased significantly among older men in the past decade, many patients appear to have normal testosterone levels and do not meet the clinical guidelines for treatment, according to new research.

Both the death rate and incidence rate for prostate cancer continues to decline, according to the latest round of statistics from leading U.S. cancer groups.

Researchers at Fred Hutchinson Cancer Research Center and the University of Washington in Seattle have developed a personalized tool that they say can predict the likelihood of prostate cancer overdiagnosis.

PSA screening has likely played an important role in the 40%-plus drop in prostate cancer mortality since the late 1980s, although the mortality rate for metastatic disease has remained the same, say study authors from the University of California, Davis.

The controversial oil and natural gas drilling technique called hydraulic fracturing, or fracking, uses many chemicals that can disrupt the body’s hormones, according to new research.

Signs of inflammation in a man’s prostate biopsy may indicate that he has a reduced risk of subsequently being diagnosed with prostate cancer in a future biopsy, according to the authors of a recently published study.

Insurance coverage has expanded for an epigenetic test for prostate cancer and percutaneous tibial nerve stimulation (PTNS) for the treatment of overactive bladder (OAB).

The top 10 Urology Times articles of 2013 encompass topics including prostate biopsy, the urology work force, and PSA screening.

The latest products and services from Lambert Academic Publishing, the AUA, United Guardian, and SpryPublishing.

Researchers say they have linked high testosterone levels in men to a poor immune response to an influenza vaccine.

With a deluge of new drug treatments for advanced prostate cancer on the market, a care model emphasizing urologist and medical oncologist collaboration is needed, according to an article whose authors represent each specialty.

Out-of-pocket costs for couples being treated for infertility range from a low of $912 for medication only to $19,234 for in vitro fertilization, according to researchers who say their data will help couples plan for the expenses they may incur.

Risk classification changed in more than half of prostate cancers following assessment of cell cycle progression in tumors, according to a study reported at the Society of Urologic Oncology meeting in Bethesda, MD.

In this article, we briefly review the evaluation of patients with PPI and discuss the benefits and drawbacks of conservative, pharmacologic, injection, and surgical treatments.

The presence of a particular protein in biopsied prostate tissue substantially increases the likelihood that cancer will develop there, according to recent study.

The FDA has approved collagenase clostridium histolyticum (CCH [XIAFLEX]) as the first medication to treat of Peyronie's disease (PD).